Covance, a global contract research organization, worked on all of the top 50 best-selling drugs available today through its full spectrum of nonclinical, clinical and commercialization services.
Covance is dedicated to advancing healthcare and delivering Solutions Made Real®
With precision delivery of the largest volume of drug development data on the planet, we can help you identify new approaches and anticipate tomorrow’s challenges. Learn more about our history and services.
Trailblazer Webinar Series: Secrets for a Biotech Breakthrough
Gain valuable insights and advice from this four-part webinar series led by industry experts and entrepreneurs on how they made their biotech dreams come alive.
Multiplex FluoroSpot-based Testing in Clinical Evaluation of Vaccines and Novel Immunotherapeutics
Join Dr. Pajon on June 21, 10:00 am EST to learn about key considerations for designing, validating and managing data with this versatile tool that advances clinical testing.
Biosimilar CMC analytical master files
Innovative & invaluable solutions for biosimilar development. Pre-developed, risk-mitigated biosimilarity assessment, testing solutions, data evaluation and consultation.
Learn how to efficiently analyze and manage your pharmacokinetic (PK) data
Gain insights in our latest blog.
Bioanalysis Education Center: Covance leads the way in bioanalytical capabilities and solutions, igniting innovation with exceptional science and timely answers.
Access the latest scientific posters, list of non-proprietary/generic assays, publications and info sheets.
Rare Disease and Orphan Drugs: accelerate complex studies globally
A range of individual approaches can be integrated to accelerate your progress of complex rare disease studies across the world. Learn how to address key development challenges.
Do you have the right precision medicine partner to optimize your program development?
The right partner can help you navigate the companion diagnostics journey from bench to bedside, starting with which pathway - IVD, LDT or both - is right for you.
End-to-end drug & diagnostic development support for a new immuno-oncology agent
Find out how Covance/LabCorp helped a prominent pharmaceutical company enable a faster, more effective launch of their immuno-oncology drug.
Proactive risk management for ICH E6 compliance
Understand the recent changes to the ICH E6 guideline. Leverage a three-tier strategy.
Designing Drug Abuse Liability Studies
Regulations from FDA, EMA and ICH M3 (R2) require GLP specific studies if a drug or its major metabolite penetrates the brain. Over the next few months, we’ll delve into these "in vivo" testing requirements and share some in-house data with you. Get a primer in our introduction post of the series.
Have you visited the NASH Education Center?
We’re pleased to announce the launch of the NASH Education Center. Access the latest thoughts from experts through webinars, case studies, blogs, info sheets and scientific articles.
Analytical methods for bioanalysis
Check out our recently updated nonproprietary assay list featuring more than 330 compounds.